Background and purpose: SERPINA3 is a protease inhibitor
belonging to the serpin super family. It has been reported that SERPINA3 expression up-regulated in various tumor cells. However
its clinical significance and biological function in endometrial cancer remains unclear. This study was aimed to investigate the effect and prognosis value of up-regulated SERPINA3 (α1-ACT) in endometrial cancer. Methods: ①We collected 20 pairs of endometrial carcinoma and normal endometrial tissues then extracted total RNA
detected SERPINA3 mRNA expression by quantitative real-time PCR; ②Immunohistochemistry was used to detect the expression of SERPINA3 in tissue chip which contained 81 endometrial cancer tissue samples and 37 normal controls endometrial tissues
based on the results
using SPSS software to analyze the relationship between SERPINA3 expression with clinicopathological features of endometrial cancer;③The highest SERPINA3 expression was selected from 5 endometrial cancer cells
then small interfering RNA targeted interference SERPINA3 gene expression; ④With real-time quantitative PCR and Western blot methods
we detected SERPINA3 gene expression in mRNA and protein levels after interference
at last
analyzed cell motility by cell migration assay. Results: ①SERPINA3 mRNA expression in endometrial carcinoma was significantly higher than the control endometrial tissue (n=20
P0.05); ②Immunohistochemistry also showed SERPINA3 expression in endometrial carcinoma higher than in normal endometrial tissues (P0.001). The analysis showed that between the expression level of SERPINA3 with endometrial cancer clinical stage
tumor differentiation
vascular invasion
lymph node metastasis
there was a close correlation (P0.05); ③Interference expression of SERPINA3
endometrial cancer cells migration was significantly reduced. Conclusion: SERPINA3 gene expression in endometrial carcinoma was significantly increased and correlated with endometrial cancer invasion and metastasis; SERPINA3 is expected to become the pathological marker of diagnosis and determination in the prognosis of endometrial cancer. It may be used as one of the biological target of endometrial cancer targeted therapy.